Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449–461.
Iwanicki-Caron I, Di Fiore F, Roque I, et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008;26:3681–3686.
Ishigami S, Sakamoto A, Uenosono Y, et al. Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer. J Surg Res 2008;148:205–209.
Yamamoto M, Baba H, Toh Y, et al. Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients. J Cancer Res Clin Oncol 2007;133:471–476.
Kim HJ, Lee KW, Kim YJ, et al. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncol 2009;48:385–390.
Takahashi Y, Takeuchi T, Sakamoto J, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 2003;6:142–145.
Kochi M, Fujii M, Kanamori N, et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 2000;3:177–186.
Ubukata H, Katano M, Motohashi G, et al. Evaluation of CA72-4 as a tumor marker in patients with gastric cancer. Gan To Kagaku Ryoho 2003;30:1821–1824.
Sheng SL, Wang Q, Huang G. Development of time-resolved immunofluorometric assays for CA 72-4 and application in sera of patients with gastric tumors. Clin Chim Acta 2007;380:106–111.
Goral V, Yesilbagdan H, Kaplan A, et al. Evaluation of CA 72-4 as a new tumor marker in patients with gastric cancer. Hepatogastroenterology 2007;54:1272–1275.
Fernandes LL, Martins LC, Nagashima CA, et al. CA72-4 antigen levels in serum and peritoneal washing in gastric cancer. Correlation with morphological aspects of neoplasia. Arq Gastroenterol 2007;44:235–239.
Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology 2003;50:1669–1674.
Ucar E, Semerci E, Ustun H, et al. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008;25:1075–1084.
Gao YC, Yuan ZB, Yang YD, et al. Effect of freeze-thaw cycles on serum measurements of AFP, CEA, CA125 and CA19-9. Scand J Clin Lab Invest 2007;67:741–747.
Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009;15:59–67.
Stein U, Dahlmann M, Walther W. MACC1-more than metastasis? Facts and predictions about a novel gene. J Mol Med 2009;88:11–18.
Kokoszynska K, Krynski J, Rychlewski L, et al. Unexpected domain composition of MACC1 links MET signaling and apoptosis. Acta Biochim Pol 2009;56:317–323.
Stein U, Smith J, Walther W, et al. MACC1 controls Met: what a difference a Sp1 site makes. Cell Cycle 2009;8:2467–2469.
Wierstra I. Sp1: emerging roles—beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 2008;372:1–13.
Yuezheng Zhang, Lianhai Zhang, Yang Gao, et al. Discovery and validation prognostic markers in gastric cancer by genome-wide expression profiling. World J Gastroenterol 2010.
American Joint Committee on Cancer: Gastric Cancer. AJCC Cancer Staging. Manual, 2002, 6th ed. pp. 99–103. New York: Springer-Verlag.
Zhang M, Zhang H, Ma Y, et al. Prognosis and surgical treatment of gastric cancer invading adjacent organs. ANZ J Surg 2010;80:510–514.
Moghimi-Dehkordi B, Safaee A, Zali M R. Survival rates and prognosis of gastric cancer using an actuarial life-table method. Asian Pac J Cancer Prev 2008;9:317–321.
Santoro R, Carboni F, Lepiane P, et al. Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg 2007;94:737–742.
Maehara Y, Kakeji Y, Oda S, et al. Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer 2000;83:986–991.
Prat M, Narsimhan RP, Crepaldi T, et al. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer 1991;49:323–328.
Okamoto W, Okamoto I, Yoshida T, et al. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther 2010;9:1188–1197.
Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213:316–325.
Shimazaki K, Yoshida K, Hirose Y, et al. Cytokines regulate c-Met expression in cultured astrocytes. Brain Res 2003;962:105–110.
Holgren C, Dougherty U, Edwin F, et al. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene 2010;29:5241–5253.
Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992;189:227–232.
Kaji M, Yonemura Y, Harada S, et al. Participation of c-met in the progression of human gastric cancers: anti-c-met oligo-nucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther 1996;3:393–404.
Amemiya H, Kono K, Itakura J, et al. c-Met expression in gastric cancer with liver metastasis. Oncology 2002;63:286–296.
Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894–1902.
Drebber U, Baldus SE, Nolden B, et al. The over-expression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 2008;19:1477–1483.